Hanmin Huang

Title: Hanmin Huang: Innovator in Pharmaceutical Research

Introduction

Hanmin Huang is a notable inventor based in Shenzhen, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds that target cancer treatment. His work exemplifies the intersection of scientific research and practical application in medicine.

Latest Patents

Hanmin Huang holds a patent for a multi-target tyrosine kinase inhibitor. This invention relates to a compound that exhibits protein kinase inhibitory activity, as represented in formula (I). The compound is metabolized into an active small molecule, td32-4, which effectively inhibits tumor growth in vivo, achieving a notable anti-tumor effect. Compared to td32-4, Huang's compound demonstrates significantly improved solubility and oral bioavailability, showcasing strong anti-tumor activity in animal experiments. The patent also details a synthetic method for the compound and its applications in the pharmaceutical field.

Career Highlights

Huang is affiliated with the Shenzhen Neptunus Pharmaceutical Research Institute Co., Ltd., where he continues to advance his research in pharmaceutical innovations. His work has garnered attention for its potential impact on cancer therapies and treatment methodologies.

Collaborations

Hanmin Huang collaborates with esteemed colleagues, including Shenglin Luan and Tian Tang, who contribute to the research and development efforts within the institute. Their combined expertise enhances the potential for groundbreaking discoveries in the pharmaceutical industry.

Conclusion

Hanmin Huang's contributions to pharmaceutical research, particularly through his innovative patent, highlight the importance of continued exploration in cancer treatment. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in the future.